Note 5 - Goodwill and Intangible Assets

12 Months Ended

Mar. 31, 2016

Goodwill and Intangible Assets Disclosure [Text Block]

Note

Goodwill and Intangible Assets

The change in the carrying amount of goodwill was as follows (in thousands):

	Biological Indicators			Instruments		Continuous Monitoring		Cold Chain			Total
March 31, 2014	$	9,279		$	14,940	$	13,647	$	--		$	37,866
Effect of foreign currency translation		--			--		--		--			--
Acquisitions		3,708			3,295		--		--			7,003
March 31, 2015		12,987			18,235		13,647		--			44,869
Effect of foreign currency translation		(624	)		--		--		(476	)		(1,100	)
Acquisitions		8,535			--		--		13,833			22,368
March 31, 2016	$	20,898		$	18,235	$	13,647	$	13,357		$	66,137

Other intangible assets are as follows:

(In thousands)	March 31, 201 6
	Carrying Amount		Accumulated Amortization		Net		Useful Life (Years)
Intellectual property	$	7,364	$	3,093	$	4,271	10	-	16
Trade names		3,474		1,271		2,203	3	-	10
Customer relationships		48,782		15,228		33,554	7	-	10
Non-compete agreements		1,846		1,077		769	3	-	10
	$	61,466	$	20,669	$	40,797

	March 31, 201 5
	Carrying Amount		Accumulated Amortization		Net		Useful Life (Years)
Intellectual property	$	7,210	$	2,362	$	4,848	10	-	16
Trade names		3,158		863		2,295	3	-	10
Customer relationships		36,408		10,752		25,656	7	-	10
Non-compete agreements		1,286		854		432	3	-	10
	$	48,062	$	14,831	$	33,231

The following is estimated amortization expense for the years ending March 31:

(In thousands)
2017	$	6,125
2018		5,951
2019		5,623
2020		5,312
2021		4,279

Amortization expense for the years ended March 31, 2016, 2015 and 2014 was $5,787,000, $4,675,000 and $2,979,000, respectively.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details